(4E)-4-[[3-[(3-methylphenyl)methoxy]phenyl]methylidene]-1-phenylpyrazolidine-3,5-dione | 429653-73-6

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 英文名称: (4E)-4-[[3-[(3-methylphenyl)methoxy]phenyl]methylidene]-1-phenylpyrazolidine-3,5-dione
• CAS: 429653-73-6
• 化学式: C₂₄H₂₀N₂O₃
• 分子量: 384.434
• InChiKey: ITMLWGWTDWJSRZ-PXLXIMEGSA-N

物化性质

• 密度：
  1.273±0.06 g/cm3(Predicted)
• 溶解度：
  DMSO：可溶5mg/mL，澄清（加热）

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  N
• 安全说明：
  S60,S61
• 危险类别码：
  R50/53
• WGK Germany：
  3
• 包装等级：
  III
• 危险类别：
  9
• 危险性防范说明：
  P273,P301+P312+P330,P305+P351+P338,P314
• 危险品运输编号：
  3077
• 危险性描述：
  H302,H319,H372,H410

制备方法与用途

生物活性

Y16是G蛋白偶联Rho GEFs抑制剂。它能阻止LARG和Rho的结合，Kd值为80 nM。

靶点

Target	Value
RhoGEFs ()

体外研究

Y16 (10-30 μΜ; 24 hours; NIH 3T3 cells) could inhibit RhoA-GTP formation induced by serum dose dependently and is specific for RhoA.
Y16 (10-30 μΜ; 24 hours; NIH 3T3 cells) efficiently inhibits serum or SDF-1α-induced phospho-MLC and phospho-FAK formation, which are downstream of RhoA.

Cell Viability Assay

Cell Line:	NIH 3T3 cells
Concentration:	10 μΜ, 30 μΜ
Incubation Time:	24 hours
Result:	Inhibited RhoA-GTP formation induced by serum dose dependently and was specific for RhoA.

Western Blot Analysis

Cell Line:	NIH 3T3 cells
Concentration:	10 μΜ, 30 μΜ
Incubation Time:	24 hours
Result:	Inhibited serum or SDF-1α-induced phospho-MLC and phospho-FAK formation, which were downstream of RhoA.

反应信息

• 作为产物：
  描述：

  Diethyl 2-[[3-[(3-methylphenyl)methoxy]phenyl]methylidene]propanedioate 、 苯肼 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 0.5h， 生成 (4E)-4-[[3-[(3-methylphenyl)methoxy]phenyl]methylidene]-1-phenylpyrazolidine-3,5-dione
  参考文献：
  名称：

  Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: Virtual screening, synthesis, and biological evaluation

  摘要：

  The identification of a novel pyrazolidine-3,5-dione based scaffold hit compound as Farnesoid X receptor (FXR) partial or full agonist has been accomplished by means of virtual screening techniques. A series of pyrazolidine-3,5-dione derivatives (1a-u and 7) was designed, synthesized, and evaluated by a cell-based luciferase transactivation assay for their agonistic activities against FXR. Most of them showed agonistic potencies and 10 of them (1a, 1b, 1d-f, 1j, 1n, 1t, 5b, and 7) exhibited lower EC(50) values than the reference drug CDCA. Molecular modeling studies for the representative compounds 1a, 1d, 1f, 1j, 1n, 1u, 5b, and 7 were also presented. The novel structural scaffold has provided a new direction for finding potent and selective FXR partial and full agonists (referred to as 'selective bile acid receptor modulators', SBARMs). (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.09.027